USPTO Notice Of Allowance Sends Micro Cap Soaring

By: Dylan Sikes – AllPennyStocks.com News

Tuesday, March 22, 2022

Whenever a company gets a nod of approval from a regulatory agency, it is usually a major feat achieved after months of hard work by the company. Just today, a biopharmaceutical company that is developing novel canner treatments for patients suffering from recurring and metastatic cancer announced that a Notice of Allowance has been received from the US Patent and Trademark Office for a specific method to treat cancer stem cells (CSC’s). This sent shares of Propanc Biopharma, Inc. (OTCQB:PPCB) soaring on the news.

Propanc Biopharma Inc. is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Traders were extremely bullish on the news as shares of Propanc climbed up to $0.0338/share (+133.10%) at the session high. This move is a breath of fresh air for long term shareholders who have been waiting for a catalyst during this slightly downtrending trading range over the last six months.

Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.